Overall rank by patents
#25,488
of 50,000 tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 3 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).
The verdict
According to USPTO PatentsView, Vascular ranks #25,488 of 50,000 tracked US assignees by granted-patent volume, with 11 patents across 3 technology areas.
USPTO PatentsView assignee plate
Corpus R25488 · US Corporation #25,488 · 11 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-UP · BOOK-FULL
Nearest grant-volume peer: Valencia Bioscience, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Vascular Access · this assignee
34 score
3D Lighting Innovati… · lowest
7 score
What this shows Vascular's Innovation Score is 33.6/100 (top 55% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Vascular Access Technologies, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). Peak complete grant year is 2023 (3 grants) versus a trough of 1 in 2015. By volume, Vascular sits between Valencia Bioscience, Inc. and Versana Micro Inc..
Vascular Access Technologies, Inc. shows 5 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Valencia Bioscience, Inc.
11 patents
Valeo Lighting Hubei Technical Center Co. Ltd.
11 patents
Valerion Therapeutics, LLC
11 patents
Vanguard Group, Inc.
11 patents
Vascular Graft Solutions Ltd.
11 patents
Ventus Therapeutics U.S., Inc.
11 patents
Veolia Nuclear Solutions, Inc.
11 patents
Versana Micro Inc.
11 patents
Vascular Access Technologies, Inc.
11 patents
What this shows Vascular holds 11 patents at rank #25,492, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #25,492 in granted patent volume.
Other assignees with the most granted patents in Vascular's primary technology class.
Vascular's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
34 Top 55% higher than 45% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 9.1% |
| 2016 | 1 | 9.1% |
| 2017 | 1 | 9.1% |
| 2019 | 2 | 18.2% |
| 2020 | 1 | 9.1% |
| 2022 | 1 | 9.1% |
| 2023 | 3 | 27.3% |
| 2024 | 1 | 9.1% |
Top 3 of 3 technology areas
Overall rank by patents
#25,488
of 50,000 tracked assignees
33.6 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.